Published in Wien Klin Wochenschr on January 31, 2004
An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J Clin Pathol (2007) 1.23
Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol (2014) 0.89
Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. BMC Cancer (2013) 0.83
[Beyond staging, typing and grading. New challenges in breast cancer pathology]. Pathologe (2010) 0.80
HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer. J Cancer Res Clin Oncol (2008) 0.78
Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer. PLoS One (2013) 0.78
Breast cancer patients should not live without a HER-2/neu tissue result--but how safe can they live with it? Wien Klin Wochenschr (2004) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer (1957) 21.59
Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science (1985) 6.56
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol (2001) 4.09
Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol (1999) 3.04
Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res (1990) 2.09
Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol (2003) 1.87
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol (1999) 1.82
Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg (2002) 1.79
Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol (1999) 1.77
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol (2001) 1.76
A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg (2002) 1.71
HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol (2001) 1.41
When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol (2001) 1.39
Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am J Surg Pathol (2003) 1.24
Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer (2003) 1.19
Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod Pathol (1998) 1.09
Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech (2002) 1.04
Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. Breast Cancer Res Treat (2001) 1.03
The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer (1994) 1.03
The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol (1999) 1.00
c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer (1999) 0.93
Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res (1996) 0.92
Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas. Eur J Cancer (1996) 0.90
Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res (2002) 0.89
Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res (2001) 0.85
Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma. Pathol Oncol Res (2001) 0.76
The use of FISH on breast core needle samples for the presurgical assessment of HER-2 oncogene status. Exp Mol Pathol (2002) 0.75
[Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)]. Wien Klin Wochenschr (1999) 0.75
[Is there progress in chemotherapy for breast cancer?]. Wien Klin Wochenschr (2001) 0.75
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med (2009) 13.74
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol (2011) 5.63
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res (2002) 2.57
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys (2007) 2.54
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst (2007) 2.34
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol (2008) 2.28
Repeat intestinal resections increase the risk of recurrence of Crohn's disease. Dis Colon Rectum (2013) 2.15
Novel clinically relevant genes in gastrointestinal stromal tumors identified by exome sequencing. Clin Cancer Res (2013) 2.04
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst (2008) 1.95
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol (2007) 1.90
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res (2012) 1.77
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg (2004) 1.72
Long-term survivorship of rotator cuff repairs using ultrasound and magnetic resonance imaging analysis. Am J Sports Med (2011) 1.69
Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst (2012) 1.69
Breast cancer issues in developing countries: an overview of the Breast Health Global Initiative. World J Surg (2008) 1.67
Influence of methylenetetrahydrofolate reductase gene polymorphisms on homocysteine concentrations after nitrous oxide anesthesia. Anesthesiology (2008) 1.66
Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis. Radiother Oncol (2006) 1.63
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin Cancer Res (2008) 1.57
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist (2013) 1.54
Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer (2003) 1.50
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat (2010) 1.50
Current value of intraoperative sonography during surgery for hepatic neoplasms. World J Surg (2002) 1.48
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol (2006) 1.44
The prevalence of hemorrhoids in adults. Int J Colorectal Dis (2011) 1.43
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol (2007) 1.42
Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2003) 1.40
Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections. World J Surg (2014) 1.39
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch (2012) 1.37
Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat (2007) 1.35
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res (2012) 1.33
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol (2012) 1.32
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol (2011) 1.31
Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointest Surg (2002) 1.26
VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery (2006) 1.24
Exact log-rank tests for unequal follow-up. Biometrics (2003) 1.24
Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res (2007) 1.22
St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care (Basel) (2013) 1.21
US-guided 14-gauge core-needle breast biopsy: results of a validation study in 1352 cases. Radiology (2008) 1.20
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer (2013) 1.17
Does gastric dilatation limit the success of sleeve gastrectomy as a sole operation for morbid obesity? Obes Surg (2006) 1.16
Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat (2006) 1.14
Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost (2003) 1.13
Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch (2002) 1.12
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer (2013) 1.11
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res (2008) 1.11
Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging. Radiology (2006) 1.09
KRAS mutations in historical tumour specimens of the Viennese Museum of pathological anatomy. Histopathology (2011) 1.08
Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res (2012) 1.08
Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group. Ann Surg (2003) 1.06
Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer (2002) 1.06
Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Ann Surg Oncol (2011) 1.06